Weekly Investment Analysts’ Ratings Updates for McKesson Corporation (MCK)

Several brokerages have updated their recommendations and price targets on shares of McKesson Corporation (NYSE: MCK) in the last few weeks:

  • 7/17/2017 – McKesson Corporation was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $187.51 price target on the stock.
  • 7/12/2017 – McKesson Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $184.00 price target on the stock. According to Zacks, “Over the past three months, McKesson has been trading above the broader Medical/Dental – Supplies industry. Looking forward, management expects to gain with the gradually stabilizing generic and branded markets. The company recently posted stable numbers for the fourth-quarter fiscal 2017 (ended Mar 31, 2017) wherein earnings beat the Zacks Consensus Estimate, courtesy of a strong performance in the Distribution Solutions division. To boost growth the company has acquired CoverMyMeds for approximately $1.1 billion in the recent past. Also, cost-savings efforts remain encouraging. Furthermore, an inexpensive valuation and rising estimate revision trend for the current year indicates a pocket of opportunity for the stock. On the flip side, stiff competition, currency headwind and reimbursement issues remain challenges.”
  • 6/29/2017 – McKesson Corporation had its price target raised by analysts at Leerink Swann to $170.00. They now have a “market perform” rating on the stock.
  • 6/27/2017 – McKesson Corporation was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $187.51 price target on the stock.
  • 6/26/2017 – McKesson Corporation had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $166.00 price target on the stock, up previously from $156.00.
  • 6/19/2017 – McKesson Corporation was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $181.27 price target on the stock.
  • 6/12/2017 – McKesson Corporation was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $181.27 price target on the stock.
  • 6/4/2017 – McKesson Corporation was given a new $187.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 5/30/2017 – McKesson Corporation had its price target raised by analysts at Mizuho from $147.00 to $168.00. They now have a “neutral” rating on the stock.
  • 5/25/2017 – McKesson Corporation had its price target raised by analysts at Morgan Stanley from $165.00 to $179.00. They now have an “overweight” rating on the stock.
  • 5/25/2017 – McKesson Corporation was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $174.15 price target on the stock.
  • 5/25/2017 – McKesson Corporation was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating.
  • 5/23/2017 – McKesson Corporation was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $189.00 price target on the stock.
  • 5/23/2017 – McKesson Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “McKesson posted stable numbers for the fourth-quarter fiscal 2017 wherein earnings beat past the Zacks Consensus Estimate owing to strong performance in the Distribution Solutions division. Over the past three months, McKesson underperformed the broader industry with respect to price performance. To boost growth the company has entered into an agreement to acquire CoverMyMeds for approximately $1.1 billion. However in the near term the company depends heavily on the pharmaceutical distribution business, which is witnessing slow growth. In addition, the company expects weaker generic pharmaceutical pricing trends in fiscal 2018. The company also anticipates lower profits in fiscal 2018 due to customer pricing activities and moderating branded pharmaceutical pricing trends. In addition, unfavorable movements in foreign exchange rates continue to hurt sales.”
  • 5/22/2017 – McKesson Corporation was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $157.10 price target on the stock.
  • 5/19/2017 – McKesson Corporation had its price target raised by analysts at UBS AG from $145.00 to $156.00. They now have a “neutral” rating on the stock.
  • 5/19/2017 – McKesson Corporation was given a new $140.00 price target on by analysts at Leerink Swann. They now have a “hold” rating on the stock.

McKesson Corporation (NYSE MCK) opened at 168.12 on Tuesday. The company has a 50-day moving average of $159.48 and a 200-day moving average of $148.28. The company has a market cap of $35.46 billion, a P/E ratio of 7.40 and a beta of 1.13. McKesson Corporation has a 52-week low of $114.53 and a 52-week high of $199.27.

McKesson Corporation (NYSE:MCK) last posted its earnings results on Thursday, May 18th. The company reported $3.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.04 by $0.35. McKesson Corporation had a net margin of 2.55% and a return on equity of 29.99%. The firm had revenue of $48.71 billion during the quarter, compared to analyst estimates of $49.48 billion. During the same quarter in the prior year, the business posted $2.44 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts expect that McKesson Corporation will post $12.10 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, July 3rd. Stockholders of record on Monday, June 5th were paid a $0.28 dividend. The ex-dividend date of this dividend was Thursday, June 1st. This represents a $1.12 annualized dividend and a dividend yield of 0.67%. McKesson Corporation’s payout ratio is 4.80%.

In other news, SVP Erin M. Lampert sold 404 shares of the company’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $160.53, for a total value of $64,854.12. Following the completion of the sale, the senior vice president now owns 2,003 shares in the company, valued at approximately $321,541.59. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Erin M. Lampert sold 809 shares of the company’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $160.66, for a total transaction of $129,973.94. Following the completion of the sale, the senior vice president now owns 59 shares of the company’s stock, valued at approximately $9,478.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,148 shares of company stock valued at $9,654,255. Company insiders own 1.20% of the company’s stock.

McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The Company operates through two segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty care products across North America and internationally.

Receive News & Ratings for McKesson Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.